查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1572281

白塞氏症治療藥物市場：按藥物類型、給藥途徑、最終用戶、藥物類別、階段、分銷管道 - 全球預測 2025-2030

Behcet Disease Drug Market by Drug Type (Corticosteroids, Immunosuppressants, Interferon-Alpha), Route of Administration (Injectable, Oral), End User, Drug Class, Stage of Disease, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年白塞氏症治療市值為4.9878億美元，預計到2024年將達到5.2256億美元，複合年成長率為4.07%，預計到2030年將達到6.5948億美元。

白塞氏症是一種罕見的自體免疫血管炎疾病，其特徵是影響多個器官的全身性發炎，為藥物開發帶來了獨特的挑戰和機會。白塞氏症的治療重點是超越標準皮質類固醇和免疫抑制劑，創造出控制症狀並減少發作頻率的治療方法。需要有標靶治療來解決眼部、口腔和全身症狀，同時盡量減少副作用，這凸顯了對先進治療的需求。最終用途範圍延伸至醫療保健提供者、藥房、專科診所和尋求改善生活品質的患者。

主要市場統計
基準年[2023] 4.9878 億美元
預測年份 [2024] 52256萬美元
預測年份 [2030] 65948萬美元
複合年成長率（%） 4.07%

關鍵的成長要素包括對白塞氏症認知的提高、生技藥品的進步以及對個人化醫療的日益重視。這些為單株抗體和小分子抑制劑等創新療法鋪平了道路。最近的趨勢是有前景的新療法進入臨床試驗，這為製藥公司提供了透過開拓新療法和解決未滿足的醫療需求來獲得競爭優勢的機會。

然而，由於白塞氏症是一種罕見疾病，市場成長受到符合臨床試驗資格的患者數量有限和藥物開發成本高昂等因素的限制。監管挑戰，特別是在不同地域市場獲得核准，使市場擴張更加複雜。

創新和研究的機會在於利用基因組學和人工智慧來發現藥物、加強患者分層和客製化治療。此外，探索發炎和免疫調節作用的途徑可能會帶來創新的治療方法。學術界和工業界之間的合作可以促進生物標記研究和精準醫學應用的進步。

白塞氏症治療市場的特點是快速的技術進步、研究主導的舉措以及行業參與者利用利基機會的策略定位。對創新研發和策略聯盟的策略重點將有助於公司滿足對有效 Behçet 療法不斷成長的需求，並確保市場持續成長。

市場動態：揭示快速發展的白塞氏症藥物市場的關鍵市場洞察

白塞氏症藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 對罕見疾病治療和研究有利的政府政策和資金
    • 各大藥企進軍白塞氏症治療市場
    • 擴大針對白塞氏症的臨床試驗和管道藥物
    • 生技公司與研究機構之間針對白塞氏症的策略合作與聯盟
  • 市場限制因素
    • 治療通訊協定的標準化很困難。
    • 由於白塞氏症是一種罕見疾病，臨床試驗的參與者數量有限，這可能會延遲藥物開發。
  • 市場機會
    • 透過教育措施提高認知和診斷率
    • 擴大對偏遠地區患者的遠距醫療服務
    • 開發和開拓針對免疫系統特定途徑的新生物製藥
  • 市場挑戰
    • 來自大型製藥企業的激烈競爭
    • 開發罕見疾病的有效治療方法高成本

波特五力：駕馭白塞氏症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對白塞氏症藥物市場的影響

外部宏觀環境因素在塑造白塞氏症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解白塞氏症治療藥物市場的競爭狀況

白塞氏症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣白塞氏症治療市場供應商的績效評估

FPNV 定位矩陣是評估白塞氏症治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了白塞氏症治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對白塞氏症治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對罕見疾病治療和研究有利的政府政策和資金
      • 各大藥企進軍白塞病藥物市場
      • 擴大白塞氏症的臨床試驗和管道藥物
      • 生物技術公司和研究機構之間針對白塞氏症的策略合作和夥伴關係
    • 抑制因素
      • 由於患者症狀和疾病進展的多樣性，治療通訊協定的標準化很困難。
      • 由於白塞氏症罕見，臨床試驗的參與者數量有限，這可能會延遲藥物開發。
    • 機會
      • 透過教育活動提高認知和診斷率
      • 擴大服務範圍，為偏遠地區的患者提供遠距醫療服務
      • 開發和商業化針對免疫系統特定途徑的新生物藥物
    • 任務
      • 與現有製藥巨頭的激烈競爭
      • 開發治療罕見疾病的有效藥物成本高昂
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章白塞氏症治療藥物市場：依藥物類型

  • 皮質類固醇
    • 潑尼松龍
    • 強的松
  • 免疫抑制劑
    • Azathioprine
    • Cyclosporine
  • α干擾素
  • 腫瘤壞死因子抑制劑
    • Adalimumab
    • Infliximab

第7章白塞氏症治療藥物市場：依給藥途徑

  • 可注射的
  • 口服

第8章白塞氏症治療藥物市場：依最終使用者分類

  • 診所
  • 家庭護理設置
  • 醫院

第9章白塞氏症治療藥物市場：依藥物類別

  • 生物製藥
    • 單株抗體
  • 小分子藥物
    • DMARD（抗逆轉錄病毒藥物）
    • NSAIDs

第10章白塞氏症治療藥物市場：依階段

  • 急性
  • 慢性的

第11章白塞氏症治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 北美和南美白塞氏症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太白塞病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章 歐洲、中東和非洲白塞氏症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C62918B2A

The Behcet Disease Drug Market was valued at USD 498.78 million in 2023, expected to reach USD 522.56 million in 2024, and is projected to grow at a CAGR of 4.07%, to USD 659.48 million by 2030.

Behcet Disease, a rare autoimmune vasculitis disorder marked by systemic inflammation that affects various organs, presents unique challenges and opportunities in drug development. The scope for Behcet Disease drugs revolves around producing treatments that manage symptoms and reduce the frequency of flares, advancing beyond standard corticosteroids and immunosuppressants. The necessity of advanced therapies is underscored by the need for targeted treatments that minimize side effects while addressing ocular, oral, and systemic manifestations. The end-use scope extends to healthcare providers, pharmacies, specialty clinics, and patients seeking improved quality of life.

KEY MARKET STATISTICS
Base Year [2023] USD 498.78 million
Estimated Year [2024] USD 522.56 million
Forecast Year [2030] USD 659.48 million
CAGR (%) 4.07%

Key growth factors include increasing awareness of Behcet Disease, advancements in biologics, and a growing emphasis on personalized medicine. These open avenues for innovative treatments like monoclonal antibodies and small-molecule inhibitors. Recent developments highlight promising new therapeutic agents entering clinical trials, presenting opportunities for pharmaceutical companies to pioneer novel therapies and gain competitive advantage by addressing unmet medical needs.

However, market growth is constrained by factors such as the rare nature of Behcet Disease, leading to limited patient populations for clinical trials, and the high cost of drug development. Regulatory challenges, particularly in obtaining approval in diverse regional markets, further complicate market expansion.

Opportunities for innovation and research lie in genomics and the use of AI for drug discovery, enhancing patient stratification, and tailoring of treatments. Additionally, exploring anti-inflammatory and immunomodulatory pathways can yield breakthrough therapies. Collaborations between academia and industry can spur progress in biomarker research and precision medicine applications.

The Behcet Disease drug market is characterized by rapid technological advancements, research-driven initiatives, and the strategic positioning of industry players to leverage niche opportunities. A strategic focus on innovative R&D and strategic collaborations can help businesses capitalize on the growing demand for effective Behcet medications, ensuring sustainable market growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Behcet Disease Drug Market

The Behcet Disease Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Favorable government policies and funding for rare disease treatment and research
    • Large pharmaceutical companies entering the Behcet's disease therapeutics market
    • Expansion of clinical trials and pipeline drugs targeting Behcet's disease
    • Strategic collaborations and partnerships between biotech firms and research institutions focused on Behcet's disease
  • Market Restraints
    • Variability in symptoms and disease progression among patients makes standardization of treatment protocols challenging
    • Limited availability of clinical trial participants due to the rare nature of Behcet disease can delay drug development
  • Market Opportunities
    • Increase awareness and diagnosis rates through educational initiatives
    • Expand services to offer remote consultations for patients in remote areas
    • Developing and marketing new biologic drugs that target specific pathways in the immune system
  • Market Challenges
    • High competition from established pharmaceutical giants
    • High costs associated with developing effective drugs for a rare disease

Porter's Five Forces: A Strategic Tool for Navigating the Behcet Disease Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Behcet Disease Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Behcet Disease Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Behcet Disease Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Behcet Disease Drug Market

A detailed market share analysis in the Behcet Disease Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Behcet Disease Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Behcet Disease Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Behcet Disease Drug Market

A strategic analysis of the Behcet Disease Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Behcet Disease Drug Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Behcet Disease Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Corticosteroids, Immunosuppressants, Interferon-Alpha, and TNF Inhibitors. The Corticosteroids is further studied across Prednisolone and Prednisone. The Immunosuppressants is further studied across Azathioprine and Cyclosporine. The TNF Inhibitors is further studied across Adalimumab and Infliximab.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals.
  • Based on Drug Class, market is studied across Biologics and Small Molecule Drugs. The Biologics is further studied across Monoclonal Antibodies. The Small Molecule Drugs is further studied across DMARDs and NSAIDs.
  • Based on Stage of Disease, market is studied across Acute and Chronic.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Favorable government policies and funding for rare disease treatment and research
      • 5.1.1.2. Large pharmaceutical companies entering the Behcet's disease therapeutics market
      • 5.1.1.3. Expansion of clinical trials and pipeline drugs targeting Behcet's disease
      • 5.1.1.4. Strategic collaborations and partnerships between biotech firms and research institutions focused on Behcet's disease
    • 5.1.2. Restraints
      • 5.1.2.1. Variability in symptoms and disease progression among patients makes standardization of treatment protocols challenging
      • 5.1.2.2. Limited availability of clinical trial participants due to the rare nature of Behcet disease can delay drug development
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase awareness and diagnosis rates through educational initiatives
      • 5.1.3.2. Expand services to offer remote consultations for patients in remote areas
      • 5.1.3.3. Developing and marketing new biologic drugs that target specific pathways in the immune system
    • 5.1.4. Challenges
      • 5.1.4.1. High competition from established pharmaceutical giants
      • 5.1.4.2. High costs associated with developing effective drugs for a rare disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Behcet Disease Drug Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Corticosteroids
    • 6.2.1. Prednisolone
    • 6.2.2. Prednisone
  • 6.3. Immunosuppressants
    • 6.3.1. Azathioprine
    • 6.3.2. Cyclosporine
  • 6.4. Interferon-Alpha
  • 6.5. TNF Inhibitors
    • 6.5.1. Adalimumab
    • 6.5.2. Infliximab

7. Behcet Disease Drug Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Behcet Disease Drug Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals

9. Behcet Disease Drug Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Biologics
    • 9.2.1. Monoclonal Antibodies
  • 9.3. Small Molecule Drugs
    • 9.3.1. DMARDs
    • 9.3.2. NSAIDs

10. Behcet Disease Drug Market, by Stage of Disease

  • 10.1. Introduction
  • 10.2. Acute
  • 10.3. Chronic

11. Behcet Disease Drug Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Americas Behcet Disease Drug Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Behcet Disease Drug Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Behcet Disease Drug Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca plc
  • 5. Bayer AG
  • 6. Biogen Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Celgene Corporation
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BEHCET DISEASE DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. BEHCET DISEASE DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. BEHCET DISEASE DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. BEHCET DISEASE DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BEHCET DISEASE DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BEHCET DISEASE DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PREDNISOLONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ACUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CHRONIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 226. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 236. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 237. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 246. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 247. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 248. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 267. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 269. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 270. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 271. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 273. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 280. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 281. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 282. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 283. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 284. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 286. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 287. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 291. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 292. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 293. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 294. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 296. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 297. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 298. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 300. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 302. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 303. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 304. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 307. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 308. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 309. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 310. FRANCE BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 311. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 313. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 314. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 315. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 316. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 317. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 318. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 319. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 320. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 321. GERMANY BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 322. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 324. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 325. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 326. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 327. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 329. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 330. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 331. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 332. ISRAEL BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 333. ITALY BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 334. ITALY BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 335. ITALY BEHCET DISEASE DRUG MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 336. ITALY BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 337. ITALY BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 338. ITALY BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 339. ITALY BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 340. ITALY BEHC